Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.J Clin Oncol. 2019 Jun 1;37(16):1391-1402PMID: 30995176 doi: 10…